recombinant spike protein

**Recombinant spike protein** is a non-specific term that usually refers to a laboratory-produced SARS-CoV-2 spike antigen used as the active immunogen in **protein subunit COVID-19 vaccines** rather than a single uniquely identifiable marketed drug product. In vaccine use, the recombinant spike protein is typically engineered to mimic the prefusion spike glycoprotein of SARS-CoV-2 and, when administered with an adjuvant, induces neutralizing antibodies and T-cell responses against the viral spike antigen to prevent COVID-19. Multiple distinct products fit this description, including full-length recombinant spike vaccines such as Novavax's adjuvanted COVID-19 vaccine and other spike-protein-based vaccines using different constructs, adjuvants, developers, and regulatory statuses, so the queried name should be treated as ambiguous unless tied to a specific product.

Other names

recombinant spike proteinrecombinant SARS-CoV-2 spike proteinrecombinant spike glycoprotein